Diaceutics Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	38.44	32.16	23.7	19.5	13.94
Revenue Growth (YoY)	19.53%	35.69%	21.51%	39.88%	9.82%
Cost of Revenue	6.96	3.89	3.99	2.76	1.71
Gross Profit	31.48	28.27	19.71	16.74	12.23
Selling, General & Admin	31.69	30.74	22.78	16.28	11.88
Other Operating Expenses	-0.26	-0.02	-0.06	-0.11	-0.2
Operating Expenses	31.44	30.73	22.72	16.17	11.68
Operating Income	0.04	-2.46	-3.02	0.58	0.55
Interest Expense	-0.06	-0.05	-0.07	-0.12	-0.09
Interest & Investment Income	-	0.6	0.65	0.11	-
Other Non Operating Income (Expenses)	0.32	-	-	-0	-
EBT Excluding Unusual Items	0.3	-1.91	-2.44	0.56	0.46
Pretax Income	0.3	-1.91	-2.44	0.56	0.46
Income Tax Expense	0.21	-0.21	-0.69	-0.16	-0.1
Net Income	0.1	-1.7	-1.75	0.72	0.56
Net Income to Common	0.1	-1.7	-1.75	0.72	0.56
Net Income Growth	-	-	-	29.05%	113.31%
Shares Outstanding (Basic)	88	84	84	84	84
Shares Outstanding (Diluted)	88	84	84	86	85
Shares Change (YoY)	4.42%	0.27%	-2.16%	1.35%	9.14%
EPS (Basic)	0.00	-0.02	-0.02	0.01	0.01
EPS (Diluted)	0.00	-0.02	-0.02	0.01	0.01
EPS Growth	-	-	-	27.29%	94.55%
Free Cash Flow	1.11	0.55	1.19	4.91	0.01
Free Cash Flow Per Share	0.01	0.01	0.01	0.06	-
Gross Margin	81.90%	87.91%	83.15%	85.83%	87.73%
Operating Margin	0.11%	-7.63%	-12.73%	2.95%	3.94%
Profit Margin	0.25%	-5.30%	-7.37%	3.71%	4.02%
Free Cash Flow Margin	2.88%	1.71%	5.00%	25.17%	0.04%
EBITDA	5.56	0.55	0.1	2.08	1.52
EBITDA Margin	14.48%	1.72%	0.43%	10.64%	10.88%
D&A For EBITDA	5.52	3.01	3.12	1.5	0.97
EBIT	0.04	-2.46	-3.02	0.58	0.55
EBIT Margin	0.11%	-7.63%	-12.73%	2.95%	3.94%
Effective Tax Rate	67.88%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.